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RESUMO
Introdução: Os benefícios da transfusão permuta parcial manual versus automatizada encontram-se pouco documentados e existem 
poucos estudos em jovens com doença falciforme. Pretendemos descrever e comparar a nossa experiência com os dois procedimen-
tos. 
Material e Métodos: Foram incluídos jovens (≤ 21 anos) que realizaram transfusão permuta parcial-manual ou -automatizada para 
prevenção ou tratamento de complicações da doença falciforme. Dados clínicos, técnicos e valores hematológicos foram recolhidos 
de forma prospectiva e analisados. 
Resultados: Realizaram-se 94 transfusões permuta parcial num período de 68 meses, 57 manuais e 37 automatizadas, 63 para pre-
venção de complicações crónicas, 30 por complicações agudas e uma no contexto pré-operatório. A redução média da hemoglobina 
S foi superior na transfusão permuta parcial-automatizada (p < 0,001) e permitiu uma redução de hemoglobina S por volume per-
mutado superior (p < 0,001), mantendo valores de hemoglobina e hematócrito estáveis. Os valores de ferritina dos doentes crónicos 
diminuíram em 54%. A principal preocupação foi a obstrução do lúmen do cateter na transfusão permuta parcial-manual e os alarmes 
de pressão do acesso na transfusão permuta parcial-automatizada. Não houve complicações major nem aloimunização. 
Discussão: A transfusão permuta parcial-automatizada reduziu a hemoglobina S de forma mais eficiente que a transfusão permuta 
parcial-manual em doentes com complicações da doença falciforme, existindo pequenos problemas relacionados com o acesso vas-
cular. O valor alvo de hemoglobina S deve ser individualizado segundo a clínica e os objetivos hematológicos. Na nossa coorte de 
jovens, a necessidade de um acesso venoso aceitável foi a principal limitação, mas a sobrecarga de ferro foi evitada.
Conclusão: A transfusão permuta parcial automatizada é segura e bem tolerada. Permite uma maior eficácia na redução da hemoglo-
bina S, um melhor controlo da volemia e a evicção da sobrecarga de ferro. 
Palavras-chave: Adolescente; Adulto Jovem; Anemia Falciforme; Criança; Transfusão de Eritrócitos/métodos
ABSTRACT
Introduction: The benefits of manual versus automated red blood cell exchange have rarely been documented and studies in young 
sickle cell disease patients are scarce. We aim to describe and compare our experience in these two procedures. 
Material and Methods: Young patients (≤ 21 years old) who underwent manual- or automated-red blood cell exchange for prevention 
or treatment of sickle cell disease complications were included. Clinical, technical and hematological data were prospectively recorded 
and analyzed. 
Results: Ninety-four red blood cell exchange sessions were performed over a period of 68 months, including 57 manual and 37 
automated, 63 for chronic complications prevention, 30 for acute complications and one in the pre-operative setting. Mean decrease 
in sickle hemoglobin levels was higher in automated-red blood cell exchange (p < 0.001) and permitted a higher sickle hemoglobin 
level decrease per volume removed (p < 0.001), while hemoglobin and hematocrit remained stable. Ferritin levels on chronic patients 
decreased 54%. Most frequent concern was catheter outflow obstruction on manual-red blood cell exchange and access alarm on 
automated-red blood cell exchange. No major complication or alloimunization was recorded. 
Discussion: Automated-red blood cell exchange decreased sickle hemoglobin levels more efficiently than manual procedure in the 
setting of acute and chronic complications of sickle cell disease, with minor technical concerns mainly due to vascular access. The 
threshold of sickle hemoglobin should be individualized for clinical and hematological goals. In our cohort of young patients, the need 
for an acceptable venous access was a limiting factor, but iron-overload was avoided. 
Conclusion: Automated red blood cell exchange is safe and well tolerated. It permits a higher sickle hemoglobin removal efficacy, 
better volume status control and iron-overload avoidance. 
Keywords: Adolescent; Anemia, Sickle Cell; Child; Erythrocyte Transfusion/methods; Young Adult
INTRODUCTION
 Sickle cell disease (SCD) is one of the commonest 
genetic disorders causing severe disease. To date no 
therapy is completely effective in the prevention and 
treatment of SCD complications. Transfusion in SCD aims 
to improve oxygen-carrying capacity while reducing the 
circulating level of sickle hemoglobin (HbS) and increasing 
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hemoglobin A, thus reducing impaired erythropoiesis, 
hemolysis and vaso-occlusive events, which are the main 
contributors for complications of SCD.1
 Red blood cell exchange (RBCX) in SCD removes 
abnormal red blood cells (RBC) and replaces them with 
donor RBCs, and is probably an underused technique. 
Compared to simple transfusion, RBCX prevents volume 
overload and viscosity rising, and is the only technique that 
rapidly decreases the levels of HbS.2
 Indications for RCBX have been classified by the 
evidence-based guidelines of the American Society for 
Apheresis (ASFA) into 4 categories3, and are summarized 
in Table 1. However, other indications may be considered 
attending to current literature: recurrent acute chest 
syndrome and recurrent vaso-occlusive crises not responsive 
to hydroxicarbamide, acute hepatic sequestration, leg ulcer, 
pulmonary hypertension, end-stage renal disease and 
progressive proliferative retinopathy.2,4-9
 To date, the benefits of manual versus automated RBCX 
have rarely been documented and studies in young patients 
are scarce. The safety and tolerability profile of automated 
RCBX procedures have been extensively reported in single-
center experiences showing a good profile in children and 
adults.10-13
 We aim to describe our pediatric experience in the 
management of SCD complications with the use of an 
automated RBCX (A-RBCX) program and compare it to our 
previous manual partial RBCX (M-RBCX) experience.
MATERIAL AND METHODS
Patients and variables
 We included all children and young adults (≤ 21 years 
old) with SCD who underwent manual or automated RBCX 
between January 2011 and August 2016 for prevention or 
treatment of complications of SCD. 
 Data were prospectively collected into a database as 
part of patient follow-up. Variables considered were: clinical 
(gender, age, weight, indication), laboratory (hematocrit-
Htc, hemoglobin-Hb, HbS%, HbF%, platelet count), packed 
RBC use, technical data (ports, duration) and complications. 
Indications and definitions
 Our protocol for RBCX in SCD contemplates the 
following indications: 
1) Acute SCD complications:
• Stroke: persistent neurological abnormality or 
transient symptoms accompanied by a new 
cerebral lesion on neuroimaging studies.
• Acute chest syndrome (ACS): infiltrate on x-ray 
(consolidation), accompanied by: chest pain, 
fever, tachypnea, wheezing or cough. Severity 
was considered when increased oxygen needs or 
mechanical respiratory support was started.
• Vaso-occlusive crisis (VOC) refractory to standard 
treatment: clinically assessed painful crisis with 
no adequate pain control after standard measures 
and optimized opioid perfusion.
2) Chronic SCD complications:
• Primary stroke prevention: when high blood flow 
velocities more than 200 cm/s on trans-cranial 
Doppler are detected.
• Secondary stroke prevention: after acute or 
overt stroke, as shown in neuroimaging studies 
(magnetic resonance / angiogram).
• Recurrent acute complications: VOC, ACS or 
priapism.
3) In the pre-operative setting of major surgery.
 
 Other indications are considered and individualized after
discussion with pediatric hematology consultants.
 Goals for HbS level are under 30% for acute stroke and 
stroke prevention, and 30% -50% in the other acute and 
chronic complications.
Table 1 - Indications for therapeutic apheresis: ASFA 2010 categories3 
ASFA category Description
I
Apheresis is accepted as first-line therapy, either as primary standalone treatment or in conjunction with other 
modes of treatment. 
II
Apheresis is accepted as second-line therapy, either as primary standalone treatment or in conjunction with 
other modes of treatment.
III Optimum role of apheresis therapy is not established. Decision making should be individual
SCD complication Acute RCBX Chronic/ Non-acute RCBX
Acute stroke I
Acute chest syndrome, severe II
Multisystem organ failure III
Severe intrahepatic cholestasis III
Priapism III
Stroke prevention with iron overload prevention II
Vaso-occlusive pain III
Presurgery III
A
R
TI
G
O
 O
R
IG
IN
A
L
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                729
Escobar C, et al. Partial red blood cell exchange in children and young patients with sickle cell disease, Acta Med Port 2017 Oct;30(10):727-733
Procedure description
 Ethical considerations: informed consent was 
obtained from the legal tutors or from the patient over 18 
years old before the procedure.
 Blood product preparation: extended blood group 
phenotyping [ABO, Rh(D,C,c,E,e), K, Jk(a), Jk(b), Fy(a), 
Fy(b) and others] and antibody screening was performed 
to each patient prior to RBCX. Packed RBC units used are 
HbS-negative, leucodepleted at the time of donation and 
irradiated (except in emergency setting). A limited donor 
policy and Duffy group genotyping (FYB gene) 14 for each 
patient is in place in our hospital Blood Bank, in collaboration 
with the Portuguese Institute for Blood and Transplantation 
(IPST, IP).
 Local and monitoring: all patients were admitted to our 
Intensive Care unit and had clinical and continuous cardio-
respiratory monitoring before, during and immediately 
after the procedure (heart rate, respiratory rate, oxygen 
saturation, blood pressure, temperature). When considered 
clinically necessary, more than one procedure was 
performed. 
 Procedure:
• Ports: a transfusion and blood removal port were 
placed. The type of venous access was recorded 
for each patient. 
• Manual RBCX procedure: continuous isovolemic 
exchange, of venesected blood for 10 - 15 mL/kg 
of packed RBC and a concomitant saline infusion, 
aiming to maintain a low hematocrit similar to the 
patient’s initial hematocrit. No limitation on patient 
weight is considered. 
• Automated RBCX procedure: Spectra Optia® 
Apheresis System (Terumo BCT) with a dedicated 
RBCX kit is in place in our PICU since December 
2014. Calcium citrate anticoagulation in a 13:1 
ratio is used. Exchange or depletion+exchange 
(isovolemic hemodilution) protocol was used 
according to the patients initial Htc and clinical 
situation. A personalized priming of the circuit with 
5% albumin or blood must be performed for patients 
with a programmed extracorporeal exchange 
volume over 10% - 15% of the total blood volume 
(Spectra Optia® Operators Manual, 2015). 
 Laboratory tests: previous to the procedure and four 
to eight hours after procedure a complete blood count, 
reticulocyte count, HbS and HbF levels were obtained. 
Ionized serum calcium was measured when symptoms of 
hypocalcemia were present. Serum ferritin was obtained 
prior to RBCX in chronic patients. 
Outcomes
 The primary outcome of the study was HbS level 
variation after M- and A-RBCX.
 The secondary outcomes were: technique indications; 
effect of RBCX on Hb, hematocrit, platelet count and HbF 
level; packed RBC utilization and efficiency; technical 
concerns and complications associated with vascular 
access and RCBX procedure.  
Statistical analysis
 Data are presented as mean ± standard deviation (SD) 
when the distribution was normal and median (range) when 
not normal. Normality was assessed using Shapiro-Wilk 
test. Manual and automated procedures were compared. 
The comparison of continuous variables was accomplished 
with parametric test Student’s t test when normality was 
assured. The comparison of categorical data in two-way 
contingency tables was performed using Fisher test. 
Statistical significance level was set at p = 0.05. Statistical 
software SPSS for Windows v19.0 was used. 
RESULTS
Cohort characteristics and indication for RBCX
 Ninety-four RBCX sessions were performed in 16 
patients over a period of 68 months. All patients were 
homozygous for HbS (HbSS) and with African family origin. 
The age ranged from 5 to 21 years old (median: 12 years 
old) and weight ranged 15 to 63 kg (median: 30 kg). Fifteen 
patients were taking hydroxicarbamide before RBCX.
 The median number of procedures per patient was two 
(range: 1 - 48 sessions), with nine patients performing only 
one or two RBCX and seven patients had three or more 
RBCX sessions. 
 RBCX were manually performed in 57 sessions and 
37 were automated. There were statistically significant 
differences in terms of age and weight in both groups. 
Gender distribution, chronic indication frequency, pre-RBCX 
hematological values and procedure duration were similar. 
The characteristics of each group are presented in Table 2. 
 In 63 cases the procedures were indicated for prevention 
Table 2 - Characteristics of RBCX groups
M-RBCX
(n = 57)
A-RBCX
(n = 37) p-value
Chronic indication 63.2% 73.0% 0.260*
Pre-RBCX Hb (g/dL) 8.2 ± 0.9 8.3 ± 1.0 0.374†
Pre-RBCX Htc (%) 23.7 ± 3 23.3 ± 2.7 0.516†
Pre-RBCX HbS (%) 60.3 ± 11.9 65.9 ± 14.4 0.047†
RBCX procedure time (minutes) 89 ± 28 
(range: 55 - 180)
95 ± 39 
(range: 33 - 196)
0.419†
Human resources 1 dedicated nurse
1 dedicated doctor
1 nurse for monitoring and alarm control
1 supervising doctor
* Fisher test; † Student’s t-test
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of chronic complications, in 30 for acute complications and 
one procedure in the pre-operative setting of laparoscopic 
cholecystectomy. The chronic and acute indications for 
RBCX in our cohort are summarized in Table 3. 
 The median follow-up for chronic patients was six 
months (range: 2 - 60 months). One young adult patient 
with overt stroke and recurrent priapism episodes was lost 
to follow-up after five A-RBCX sessions. 
Vascular access
 The most common venous port used for blood removal 
was central venous catheter (CVC) (84 sessions, 89.4%). 
In ten cases of RBCX the same CVC with two lumens was 
used for both blood removal and transfusion, and in eight 
cases two CVC had to be placed. Peripheral access was 
only used for blood removal in two cases of M-RBCX and 
was tried in four cases of A-RBCX without success due to its 
low blood outflow. Peripheral venous access for transfusion 
was used in 44 sessions (46.8%).
 Only one patient had long-term port placed for trans-
fusion for secondary stroke prevention in RBCX program: 
one was used for 14 M-RBCX sessions before being 
removed due to infection and a second one was used for 
18 sessions. In this same patient, an arteriovenous fistula 
(AVF) in the forearm was created as a venous access 
for RBCX and was used in three manual procedures for 
bleeding and transfusion before AVF thrombosis. 
Hematological outcomes 
 The mean decrease in HbS levels was higher in A-RBCX 
procedures (-46% vs -27%; p < 0.001) while hemoglobin and 
hematocrit remained stable in both procedures (Table 4). 
The platelet count was highly decreased during automated 
sessions when compared to manual procedure (-33% vs 
-20%; p < 0.001) but platelet count lower than 100 000 / 
mm3 did not occur. In 34 A-RBCX procedures HbF levels 
were recorded before and after the procedure, with a mean 
decrease of 47.6%. 
 Ferritin levels were recorded for the five patients on the 
chronic transfusion program. One patient with concomitant 
ulcerative colitis has persistent low ferritin values due to 
frequent gastro-intestinal bleeding, and was not considered. 
One patient presented with iron overload with ferritin levels 
over 1400 ng/mL at the start of the RBCX program and was 
treated with deferoxamine plus A-RBCX during one year 
with a reduction and stabilization of ferritin serum levels to 
300 ng/mL. The other three patients had received simple 
transfusions prior to chronic A-RBCX and ferritin levels 
reduced (median: initial serum ferritin: 223 ng/mL, last 
ferritin value: 112 ng/mL, variation: -54%) after a median of 
five A-RBCX sessions. 
Packed red cell use and efficiency
 The mean blood consumption of packed RBC per 
patient weight was 10.5 ± 3.3 mL/kg in M-RBCX and 19.7 ± 
6.2 mL/kg in A-RBCX (p < 0.001). Isovolemic hemodilution 
Table 3 - Indications for RBCX in our cohort by technique
M-RBCX A-RBCX Total
Acute complications 21 9 30
  Acute chest syndrome 10 2 12
  Refractory VOC 4 5 9
  ACS + refractory VOC 5 0 5
  Priapism 1 1 2
  Acute stroke 1 - 1
  Extensive subgaleal hematoma due to extramedullary hematopoiesis - 1 1
Chronic complications 36 27 63
  Secondary stroke prevention* 35 16 51
  Primary stroke prevention 1 7 8
  Recurrent VOC 0 4 4
  Recurrent priapism* 0 5 5
Pre-operative - 1 1
* one patient with both indications
Table 4 - Hematological outcomes in manual and automated RBCX (Mean ± SD)
Pre-RBCX* Post-RBCX Variation
M-RBCX A-RBCX M-RBCX A-RBCX M-RBCX A-RBCX p-value (t-test)
Hb (g/dL) 8.6 ± 0.6 8.4 ± 0.9 9.3 ± 0.7 8.6 ± 0.8 +7.2 ± 5.3% +2.1 ± 11.2% 0.284
Htc (%) 24.4 ± 1.9 23.5 ± 2.5 25.4 ± 2.4 23.8 ± 2.1 +4.1 ± 3.7% +2.5 ± 11.6% 0.374
HbS (%) 56.0 ± 9.2 66.3 ± 14.6 41.3 ± 11.1 35.8 ± 11.4 -27.2 ± 7.8% -46.2 ± 11.0% < 0.001
HbF (%)† 9.7 ± 4.2 10.9 ± 6.4 7.9 ± 4.0 5.6 ± 3.3 -18.8 ± 24.0% -47.6 ± 17.0% 0.002
Platelets (103/uL) 338 ± 49 393 ± 159 268 ± 47 256 ± 100 -20.3 ± 10.2% -32.8 ± 15.0% < 0.001
* simple transfusion previous to RBCX was performed in 14 cases; † values available for 34 procedures: 5 in M-RBCX & 29 in A-RBCX
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(depletion + exchange protocol) on A-RBCX was used in 14 
sessions (38% of A-RBCX procedures), with a median use 
of 115 mL of saline (range: 50 - 360 mL) in each procedure. 
 A-RBCX permitted a higher decrease of HbS level per 
volume removed (-2.1 ± 0.6% per mL/kg of volume removed 
vs -1.3 ± 0.6% per mL/kg; p < 0.001) although removal 
volumes were equal between RBCX procedures (23.8 ± 
12.2 mL/kg in M-RBCX vs 23.1 ± 6.3 mL/kg in A-RBCX; p = 
0.500). Removal volume in M-RBCX consists of venesected 
total blood while on A-RBCX is mainly the RBC fraction after 
centrifugation.  
Procedure concerns and complications
 Vascular access management was the most frequent 
concern during procedures: catheter outflow obstruction in 
manual blood removal (n - 8), solved after saline wash-out of 
the circuit or replacement of stopcock and extension tubing; 
access alarm on A-RBCX equipment due to excessive 
pressure in return or removal circuit (n - 7), solved changing 
the patient position, flushing the catheter with saline, 
decreasing the inlet rate, or reversing the catheters lumens 
when the same port was used for transfusion and removal.
 Other vascular port related complications were 
implantable venous port infection (n - 1) and AVF thrombosis 
(n - 1), and both occurred in the same patient while on the 
M-RBCX program. 
 Other minor complications included hypotension (n - 3) 
and transitory hypothermia (n - 1), both in M-RBCX. There 
were no metabolic or electrolyte imbalances, as well as no 
symptoms of acute hypocalcemia.  
 After 154 packed RBC units transfused in RBCX, there 
was no record of alloantibodies development or transfusion 
reactions.  
DISCUSSION 
 In this study, we present our single-center cohort 
experience of RBCX procedures for the prevention and 
treatment of SCD complications in young patients. To our 
knowledge, this is the only report of pediatric A-RBCX 
experience in Portugal. 
 We aimed to compare our manual vs automated RBCX 
experience, and although there were statistically diferences 
in terms of age and weight between both groups, we did not 
find that those differences affected the patient management.
 In our cohort, A-RBCX decreased HbS levels more 
efficiently than manual procedure in the setting of acute and 
chronic complications of SCD, with minor technical concerns 
mainly due to vascular access difficulty. This further 
reduction in HbS observed with automated procedures is 
explained not only by the greater amount of packed RBC 
used, but also because A-RBCX permits the separation of 
the RBC fraction of blood and reutilization of the patients 
own plasma, thus allowing higher exchange volumes. In 
both procedures, hemoglobin and hematocrit remained 
in the expected ranges, which allowed overcoming the 
hyperviscosity associated with simple transfusion. 
 A threshold for HbS level under 30% has been 
recommended for patients with complications of SCD.2 
However, some authors agree that a higher threshold 
between 40% - 50% may be acceptable in patients without 
recurrence of stroke in the first 24 months, patients 
with only abnormal TCD results or patients with acute 
complications besides stroke.15,16 For patients with recurrent 
VOC a threshold of < 50% has been proposed.2 Achieving 
a HbS level threshold of 30% or less may be associated 
with higher blood requirements and more frequent RBCX 
procedures and in our opinion the HbS threshold should be 
individualized according with clinical goals, especially in the 
acute setting. The higher packed RBC volume needed to 
perform A-RBCX could represent a concern for blood banks 
in some centers.
 A higher platelet removal in the automated technique 
could be a limitation to remove higher blood volumes, but 
in our cohort we did not find any severe thrombocytopenia. 
The clinical significance of the reduction HbF levels in 
patients enrolled in the chronic RBCX program is unknown, 
and should be further analyzed. 
 Regarding ACS treatment, the better control of 
hyperviscosity and volume status associated with RBCX 
favors the use of this technique instead of simple transfusion 
as the first-line therapy in moderate and severe cases, when 
a rapid decrease in HbS is needed, and also in patients with 
a high baseline Hb value.2,9,17
 Albeit not consensual, in our opinion RBCX should also 
be considered as an additional therapy for refractory pain 
due to VOC after optimization of opioid infusion. A higher 
depuration of opioids during the procedure should be taken 
into account and analgesia should be monitored, although 
in our experience we did not find it a relevant issue once 
improvement of complaints was registered a few hours after 
RBCX and opioids could be decreased. 
 For children and young adults included in chronic 
transfusion programs, the need for an acceptable venous 
access can be a limiting factor, with a high rate of central 
port placement.8,10 Moreover, sedation and expertise for 
central line insertion requires a trained healthcare team. 
In our institution, children on the chronic RBCX program 
are admitted to PICU for 24 hours or less to perform the 
procedure. Blood removal in RBCX requires a good blood 
outflow that we were not able to achieve with peripheral 
venous access, probably due to vein size and cannulation 
difficulties. In the experience of other authors, arteriovenous 
fistula, long-term dual lumen implantable ports or even 
peripheral access have proved successful in adults16,18 
and children8 with SCD in chronic erythrocytapheresis 
programs. Our AVF attempt was not successful, probably 
due to the size of the patient, and a long-term single-port 
subcutaneous catheter was placed in this child. 
 Alloimmunization has been a frequently described 
complication of multiple transfusions in adults with SCD.9 
This complication is especially important in countries like 
Portugal, with donors mainly of Caucasian origin and 
sickle cell patients of African origin. In our experience no 
cases of alloantibodies were found, probably due to an 
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extensive blood group matching and limited donor policy. 
Nevertheless, recent literature in SCD patients has proved 
that RBCX does not increase the risk of alloimmunization 
even though the blood requirement and donor exposure is 
higher.19-20
 Although not a main endpoint of our study, ferritin 
levels of our patients on chronic RBCX were always in 
the normal range and so no iron-overload complications 
were observed. One patient needed chelation therapy with 
deferasirox, due to multiple single transfusions as part of 
the chronic transfusion program for secondary prevention 
of stroke that was performed before starting RCBX. After 
starting the monthly A-RBCX program a decrease in ferritin 
levels was observed and chelation therapy was stopped. 
Iron overload is directly associated with transfusion 
method and its duration,21 and can have serious long-
term consequences during adulthood, including hepatic 
cirrhosis, cardiac damage, diabetes, hypogonadism and 
pulmonary hypertension.22-24 A-RBCX is the method that 
is associated with the lowest iron accumulation rate of 
all transfusion regimens24 and has also proved to be an 
effective method to reduce iron overload in chronically 
transfused patients.25 Prevention of iron overload instead of 
treating its consequences is a major health goal in our care 
for children with sickle cell disease. 
 Despite the fact that A-RBCX is easier to perform 
and less human resource consuming, it is not feasible 
in all settings due to the need of specific and expensive 
equipment. In this context, manual RBCX still has a role in 
centers without apheresis systems. In our experience, this is 
a feasible and safe procedure that can be readily performed 
in the setting of acute complications of SCD to lower HbS 
levels.26 However, in the long-term and whenever available, 
automated procedures should be preferred for their ability 
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to maintain lower HbS values, to allow more spaced 
procedures and avoid iron-overload.11 Further studies 
should address other indications for RCBX, especially in the 
pediatric population where prevention should start as early 
as needed. 
CONCLUSION
 Partial red cell exchange was shown to be a safe and 
well tolerated technique for the prevention and treatment 
of complications of sickle cell disease in our cohort. A 
higher HbS removal efficacy, better volume status control 
and iron-overload avoidance makes automated RBCX a 
prefered technique than compared to manual partial RBCX 
and should always be preferred in long-term transfusion 
programs.
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